

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **July 29, 2020**

ABBVIE INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or other Jurisdiction
of Incorporation)

001-35565
(Commission File Number)

32-0375147
(IRS Employer
Identification No.)

1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(847) 932-7900**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 Par Value	ABBV	New York Stock Exchange Chicago Stock Exchange
1.375% Senior Notes due 2024	ABBV24	New York Stock Exchange
0.750% Senior Notes due 2027	ABBV27	New York Stock Exchange
2.125% Senior Notes due 2028	ABBV28	New York Stock Exchange
1.250% Senior Notes due 2031	ABBV31	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is certain unaudited financial information relating to the acquisition by AbbVie Inc. (“AbbVie”) of Allergan plc (“Allergan”), which closed on May 8, 2020. On page 1, AbbVie provides information with respect to its historical key product revenues for each of the quarters in the year ended December 31, 2019, the year ended December 31, 2019 as well as the quarter ended March 31, 2020. On page 2, AbbVie provides information with respect to its comparable key product revenues for each of the quarters in the year ended December 31, 2019, the year ended December 31, 2019 as well as the quarter ended March 31, 2020, which was prepared as if the acquisition of Allergan had closed on January 1, 2019.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Certain unaudited financial information relating to the acquisition by AbbVie Inc. of Allergan plc (furnished pursuant to Item 2.02).
104	The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date: July 29, 2020

By: /s/ Robert A. Michael

Robert A. Michael

Executive Vice President, Chief Financial Officer

AbbVie Inc.
Key Product Revenues
Quarterly Trend Analysis
(Unaudited, in millions)

	1Q19			2Q19			3Q19			4Q19			FY19			1Q20		
	U.S.	Int'l.	Total	U.S.	Int'l.	Total	U.S.	Int'l.	Total	U.S.	Int'l.	Total	U.S.	Int'l.	Total	U.S.	Int'l.	Total
NET REVENUES	\$5,270	\$2,558	\$7,828	\$5,964	\$2,291	\$8,255	\$6,244	\$2,235	\$8,479	\$6,429	\$2,275	\$8,704	\$23,907	\$9,359	\$33,266	\$6,158	\$2,461	\$8,619
Immunology	3,215	1,231	4,446	3,835	1,083	4,918	3,977	1,064	5,041	4,195	971	5,166	15,222	4,349	19,571	4,004	1,085	5,089
Humira	3,215	1,231	4,446	3,793	1,077	4,870	3,887	1,049	4,936	3,969	948	4,917	14,864	4,305	19,169	3,656	1,047	4,703
Skyrizi	—	—	—	42	6	48	76	15	91	193	23	216	311	44	355	266	34	300
Rinvoq	—	—	—	—	—	—	14	—	14	33	—	33	47	—	47	82	4	86
Hematologic Oncology	934	239	1,173	1,003	265	1,268	1,184	294	1,478	1,230	317	1,547	4,351	1,115	5,466	1,167	382	1,549
Imbruvica ^a	829	193	1,022	886	213	1,099	1,042	215	1,257	1,073	223	1,296	3,830	844	4,674	966	266	1,232
Venclexta	105	46	151	117	52	169	142	79	221	157	94	251	521	271	792	201	116	317
Aesthetics	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Botox Cosmetic*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Juvederm Collection*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Aesthetics*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Neuroscience	22	89	111	24	91	115	26	91	117	25	93	118	97	364	461	25	99	124
Botox Therapeutic*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Vraylar*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Duodopa	22	89	111	24	91	115	26	91	117	25	93	118	97	364	461	25	99	124
Ubrelyvy*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Neuroscience*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Eye Care	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Lumigan/Ganfort*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Alphagan/Combigan*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Restasis*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Eye Care*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Women's Health	13	—	13	18	1	19	27	—	27	33	1	34	91	2	93	30	1	31
Lo Loestrin*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Orilissa	13	—	13	18	1	19	27	—	27	33	1	34	91	2	93	30	1	31
Other Women's Health*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Key Products	1,003	425	1,428	1,024	425	1,449	1,017	370	1,387	976	367	1,343	4,020	1,587	5,607	910	363	1,273
Mavyret	403	387	790	396	384	780	368	327	695	306	322	628	1,473	1,420	2,893	234	325	559
Creon	227	—	227	257	—	257	265	—	265	292	—	292	1,041	—	1,041	276	—	276
Lupron	191	38	229	168	41	209	187	43	230	174	45	219	720	167	887	195	38	233
Linzess/Constella*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Synthroid	182	—	182	203	—	203	197	—	197	204	—	204	786	—	786	205	—	205

^a Reflects profit sharing for Imbruvica international revenues.

* Represents product(s) acquired as part of the Allergan acquisition.

AbbVie Inc.
Key Product Revenues
Quarterly Comparable Historical Trend Analysis^{a, b}
(Unaudited, in millions)

	1Q19			2Q19			3Q19			4Q19			FY19			1Q20		
	U.S.	Int'l.	Total	U.S.	Int'l.	Total	U.S.	Int'l.	Total	U.S.	Int'l.	Total	U.S.	Int'l.	Total	U.S.	Int'l.	Total
NET REVENUES	\$8,031	\$3,359	\$ 11,390	\$ 9,130	\$ 3,137	\$ 12,267	\$ 9,334	\$ 3,069	\$ 12,403	\$ 9,751	\$ 3,192	\$ 12,943	\$ 36,246	\$ 12,757	\$ 49,003	\$ 9,018	\$ 3,151	\$ 12,169
Immunology	3,215	1,231	4,446	3,835	1,083	4,918	3,977	1,064	5,041	4,195	971	5,166	15,222	4,349	19,571	4,004	1,085	5,089
Humira	3,215	1,231	4,446	3,793	1,077	4,870	3,887	1,049	4,936	3,969	948	4,917	14,864	4,305	19,169	3,656	1,047	4,703
Skyrizi	—	—	—	42	6	48	76	15	91	193	23	216	311	44	355	266	34	300
Rinvoq	—	—	—	—	—	—	14	—	14	33	—	33	47	—	47	82	4	86
Hematologic Oncology	934	239	1,173	1,003	265	1,268	1,184	294	1,478	1,230	317	1,547	4,351	1,115	5,466	1,167	382	1,549
Imbruvica ^c	829	193	1,022	886	213	1,099	1,042	215	1,257	1,073	223	1,296	3,830	844	4,674	966	266	1,232
Venclexta	105	46	151	117	52	169	142	79	221	157	94	251	521	271	792	201	116	317
Aesthetics	648	353	1,001	737	357	1,094	646	358	1,004	742	413	1,155	2,773	1,481	4,254	587	250	837
Botox Cosmetic*	230	147	377	252	176	428	238	166	404	272	183	455	992	672	1,664	213	114	327
Juvederm Collection*	129	158	287	157	173	330	135	144	279	167	181	348	588	656	1,244	108	113	221
Other Aesthetics*	289	48	337	328	8	336	273	48	321	303	49	352	1,193	153	1,346	266	23	289
Neuroscience	780	185	965	903	192	1,095	923	189	1,112	1,005	198	1,203	3,611	764	4,375	919	192	1,111
Botox Therapeutic*	403	94	497	454	99	553	439	93	532	469	103	572	1,765	389	2,154	402	89	491
Vraylar*	148	—	148	201	—	201	241	—	241	291	—	291	881	—	881	285	—	285
Duodopa	22	89	111	24	91	115	26	91	117	25	93	118	97	364	461	25	99	124
Ubrelvy*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	13	—	13
Other Neuroscience*	207	2	209	224	2	226	217	5	222	220	2	222	868	11	879	194	4	198
Eye Care	505	292	797	594	327	921	577	313	890	610	319	929	2,286	1,251	3,537	607	283	890
Lumigan/Ganfort*	70	85	155	69	91	160	69	89	158	79	96	175	287	361	648	81	81	162
Alphagan/Combigan*	91	38	129	98	41	139	94	40	134	95	43	138	378	162	540	92	37	129
Restasis*	248	10	258	315	12	327	300	10	310	331	18	349	1,194	50	1,244	314	11	325
Other Eye Care*	96	159	255	112	183	295	114	174	288	105	162	267	427	678	1,105	120	154	274
Women's Health	230	8	238	262	10	272	280	11	291	285	13	298	1,057	42	1,099	219	9	228
Lo Loestrin*	129	3	132	150	3	153	167	3	170	161	5	166	607	14	621	114	3	117
Orilissa	13	—	13	18	1	19	27	—	27	33	1	34	91	2	93	30	1	31
Other Women's Health*	88	5	93	94	6	100	86	8	94	91	7	98	359	26	385	75	5	80
Other Key Products	1,181	430	1,611	1,231	430	1,661	1,237	377	1,614	1,216	374	1,590	4,865	1,611	6,476	1,103	370	1,473
Mavyret	403	387	790	396	384	780	368	327	695	306	322	628	1,473	1,420	2,893	234	325	559
Creon	227	—	227	257	—	257	265	—	265	292	—	292	1,041	—	1,041	276	—	276
Lupron	191	38	229	168	41	209	187	43	230	174	45	219	720	167	887	195	38	233
Linzess/Constella*	178	5	183	207	5	212	220	7	227	240	7	247	845	24	869	193	7	200
Synthroid	182	—	182	203	—	203	197	—	197	204	—	204	786	—	786	205	—	205

^a Comparable historical net revenues include total revenues for all reported periods for both AbbVie and Allergan products as if the acquisition had closed on January 1, 2019.

^b All historically reported Allergan revenues have been recast to conform to AbbVie's revenue recognition accounting policies and reporting conventions for certain rebates and discounts. Historically reported Allergan revenues also exclude Zenpep and Viokace product revenues, which were both divested as part of the acquisition, as well as specified items.

^c Reflects profit sharing for Imbruvica international revenues.

* Represents product(s) acquired as part of the Allergan acquisition.